Posted on 5/17/17
MTBC Expands Relationship with New Jersey-based Regional Health System
MTBC (NASDAQ: MTBC) (NASDAQ: MTBCP), a leading provider of proprietary, cloud-based electronic health records, practice management and mHealth solutions, today announced that Saint Clare's Health, an . . .
Posted on 5/17/17
Johnson & Johnson Updates Investors
Johnson & Johnson (NYSE:JNJ) will host a business review this morning updating analysts on its pharmaceutical pipeline, including Actelion. Key highlights:More than 50 regulatory submissions expected . . .
Posted on 5/17/17
Why You Should Feel Nervous If Johnson & Johnson Hits $140
On Monday, Johnson & Johnson (NYSE:JNJ) closed at 126.99, 1.56% below its 52-week high of 129.00, set on Mar 15, 2017."You read it on the Financial . . .
Posted on 5/17/17
Celgene Sales And Pipeline Keeping Pace With Expectations
Celgene Corporation (NASDAQ:CELG) is a $93-billion market cap pharmaceutical giant "focused on changing the course of human health through bold pursuits in science, life enhancing therapies . . .
Posted on 5/17/17
Pfizer: There Is No Upside Without M&A
Despite a 3.8% dividend yield and a solid free cash flow generation, I don't think Pfizer (NYSE:PFE) offers a compelling risk/reward, even if the stock is . . .
Posted on 5/17/17
Teva Pharmaceuticals: How Safe Is The High Dividend Yield?
Certain large pharmaceutical companies have proven to be excellent high-yield dividend growth stocks. However, due to the cyclical nature of the business, high R&D costs, and . . .
Posted on 5/16/17
Agile Therapeutics: No Reason For The FDA To Approve Another Inferior Patch
Company SynopsisAgile Therapeutics (NASDAQ:AGRX) is a clinical-stage biotech company located in Princeton, New Jersey. It is developing hormonal contraceptive products utilizing Skinfusion for transdermal delivery of . . .
Posted on 5/16/17
3 Biotech Stocks I'd Buy Right Now
Biotech stocks across the board have had a great year so far, but Cara Therapeutics Inc.(NASDAQ:CARA), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), and Omeros Corporation (NASDAQ:OMER) have flown . . .
Posted on 5/15/17
Bellerophon Reports Q1 2017 Financial Results and Provides Business Update
WARREN, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for . . .
Posted on 5/15/17
Merck Cements Its Lung Cancer Lead
Immuno-oncology is Merck & Co's (NYSE:MRK) world - everyone else just lives in it. US approval of Keytruda in first-line non-small cell lung cancer in combination . . .
Posted on 5/15/17
Johnson & Johnson: Buy And Hold Forever
Johnson & Johnson (NYSE:JNJ) is a multinational pharmaceutical, consumer products and medical equipment company which has stood the test of time. The company, which was founded . . .
Posted on 5/15/17
Here's How Much Teva Pharmaceutical Could Net From the Sale of Non-Core Assets
On Wednesday, May 10, we looked at four of the most pressing questions shareholders (including yours truly) had heading into Teva Pharmaceutical Industries' (NYSE:TEVA) first-quarter earnings . . .
Posted on 5/15/17
Johnson & Johnson: A Fantastic Company With A Great Dividend
Johnson & Johnson (NYSE:JNJ) is a multinational pharmaceutical, consumer products and medical equipment company which has stood the test of time. The company, which was founded . . .
Posted on 5/12/17
Celsion Corp. Reports Q1 2017 Financial Results and Provides Business Update
LAWRENCEVILLE, N.J., May 12, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, . . .
Posted on 5/12/17
Actavis Generics Acquisition Drives Teva Pharmaceutical Industries Ltd. First-Quarter Sales Higher
A boost from the acquisition of Actavis Generics from Allergan (NYSE:AGN) made the difference for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) when the company reported its results . . .
Posted on 5/12/17
Celgene: Fears Over Revlimid Create A Buying Opportunity
Celgene (NASDAQ:CELG) is down over 2 percent since a downgrade by Argus Research on Friday over a concern that it was becoming too reliant on Revlimid . . .
Posted on 5/11/17
Better Buy: GlaxoSmithKline vs. Johnson & Johnson
The stocks of big pharmaceutical companies are usually not very exciting, but that's just fine for savvy investors who value safe dividends and the fact that . . .
Posted on 5/11/17
4 Pressing Questions We Want Answered When Teva Pharmaceutical Reports Tomorrow Morning
We're in the thick of earnings season, which means some of the most prominent industry leaders are set to report their quarterly results. Tomorrow morning, Israel-based . . .
Posted on 5/11/17
Inovio Pharmaceuticals Reports 2017 First Quarter Financial Results
PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended March 31, 2017.Total revenue was . . .
Posted on 5/9/17
FDA Grants Fast Track Designation to XyloCor Therapeutics Lead Candidate XC001
NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--XyloCor Therapeutics Inc., a privately held biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation . . .
Posted on 5/8/17
Juno Therapeutics Q1 Revenue Improves Thanks to Celgene Collaboration
When Juno Therapeutics (NASDAQ:JUNO) announced its fourth-quarter and full-year 2016 results in March, investors were most focused on the company's discontinuation of development of a once-promising . . .
Posted on 5/8/17
A Strong Case for Buying Celgene
The pharmaceutical industry can present a growth investor with a dilemma: Should I settle for the slow growth of the big drug companies to get safety, . . .
Posted on 5/8/17
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
Concentrating firepower on hard-to-treat viruses made Gilead Sciences (NASDAQ:GILD) one of the world's most profitable companies in recent years. In fact, the biotech's cash flows topped . . .
Posted on 5/8/17
Better Buy: Amgen Inc. vs. Johnson & Johnson
Investors who bought shares of Amgen (NASDAQ:AMGN) five years ago are probably a happier bunch than those who went for Johnson & Johnson (NYSE:JNJ). Amgen stock . . .
Posted on 5/8/17
Aqua America, Inc. 2017 Q1 - Results - Earnings Call Slides
The following slide deck was published by Aqua America, Inc. in conjunction with their 2017 Q1 earnings call. 124READ FULL ARTICLE HERE

